Equity Overview
Price & Market Data
Price: $1.26
Daily Change: +$0.10 / 7.94%
Range: $1.15 - $1.27
Market Cap: $89,623,920
Volume: 568,082
Performance Metrics
1 Week: 18.87%
1 Month: -1.56%
3 Months: -45.45%
6 Months: -47.28%
1 Year: -70.70%
YTD: -42.47%
Company Details
Employees: 82
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.